Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3699MR)

This product GTTS-WQ3699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9833MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5761MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ1847MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ1480MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ9774MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ5292MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5402MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW